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Abstract Small molecule inhibitors of epidermal growth fac-
tor receptor (EGFR) tyrosine kinase activity, such as erlotinib
and gefitinib, revolutionized therapy for non-small cell lung
cancer (NSCLC) patients whose tumors harbor activating
EGFR mutations. However, mechanisms to overcome the
invariable development of acquired resistance to such agents,
as well as realizing their full clinical potential within the
context of wild-type EGFR (WT-EGFR) disease, remain to
be established. Here, the antitumor efficacy of targeted EGFR
tyrosine kinase inhibitors (TKIs) and the HSP90 inhibitor
ganetespib, alone and in combination, were evaluated in
NSCLC. Ganetespib potentiated the efficacy of erlotinib in
TKI-sensitive, mutant EGFR-driven NCI-HCC827 xenograft
tumors, with combination treatment causing significant tumor
regressions. In erlotinib-resistant NCI-H1975 xenografts, con-
current administration of ganetespib overcame erlotinib resis-
tance to significantly improve tumor growth inhibition.
Ganetespib co-treatment also significantly enhanced antitu-
mor responses to afatinib in the same model. In WT-EGFR
cell lines, ganetespib potently reduced cell viability. In NCI-
H1666 cells, ganetespib-induced loss of client protein expres-
sion, perturbation of oncogenic signaling pathways, and in-
duction of apoptosis translated to robust single-agent activity
in vivo. Dual ganetespib/erlotinib therapy induced regressions
in NCI-H322 xenograft tumors, indicating that the sensitizing
properties of ganetespib for erlotinib were conserved within
theWT-EGFR setting. Mechanistically, combined ganetespib/
erlotinib exposure stabilized EGFR protein levels in an inac-
tive state and completely abrogated extracellular-signal-
regulated kinase (ERK) and AKT signaling activity. Thus,
selective HSP90 blockade by ganetespib represents a poten-
tially important complementary strategy to targeted TKI inhi-
bition alone for inducing substantial antitumor responses and
overcoming resistance, in both the mutant and WT-EGFR
settings.
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Introduction
Lung cancer remains the leading cause of cancer mortality
worldwide [1], with almost 160,000 deaths estimated for 2013
in the USA alone [2]. Non-small cell lung cancer (NSCLC)
accounts for the majority (85 %) of all cases. Platinum-based
combination chemotherapy provides the foundation for
standard-of-care treatments in the clinical management of
advanced NSCLC; unfortunately, this strategy has largely
reached a plateau of effectiveness in improving overall sur-
vival rates for patients [3, 4]. NSCLC is characterized by a
remarkable degree of genetic diversity and may be further
classified into distinct molecular subsets based on genotypic
alterations that act as oncogenic drivers of malignancy in this
disease [5, 6]. Over recent years, an increased biological
understanding of NSCLC tumorigenesis has transformed lung
cancer therapy from broad-based cytotoxic use toward more
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tailored treatment approaches for certain NSCLC patient pop-
ulations [7]. This paradigm shift has, in turn, provided mean-
ingful improvements in overall survival and quality of life [5,
7].
A prime example is provided by targeted inhibitors of the
epidermal growth factor receptor (EGFR), which revolution-
ized and modified the principles of NSCLC treatment a de-
cade ago [8]. EGFR is a member of the ErbB family of
transmembrane receptor tyrosine kinases (EGFR/ErbB1, hu-
man epidermal growth factor receptor 2 (HER2)/ErbB2,
HER3/ErbB3, and HER4/ErbB4). EGFR activation stimu-
lates a variety of intracellular signaling cascades, including
the JAK/signal transducers and activators of transcription
(STAT), RAS/RAF/extracellular-signal-regulated kinase
(ERK), and PI3K/AKT pathways [9]. In tumor cells, EGFR
activity may become dysregulated through a number of mech-
anisms, including activating mutations, amplification of gene
copy number, and/or receptor overexpression [10]. EGFR
overexpression is a feature of NSCLC tumors, particularly in
patients with metastatic disease, and is correlated with poor
prognosis [11]. Gefitinib and erlotinib, both small-molecule
EGFR tyrosine kinase inhibitors (TKIs), were the first molec-
ularly targeted agents used in the treatment of advanced
NSCLC. Dramatic tumor responses and favorable clinical
outcomes led to their widespread use in the first-line setting
for NSCLC patients bearing activating EGFR mutations.
However, durable responses to either TKI are rare due to the
invariable development of resistance, which commonly arises
through the acquisition of a second-site mutation (T790M)
within EGFR [12, 13], or via activation of compensatory
signaling pathways that bypass the receptor and restore down-
stream oncogenic signaling [14]. Strategies to counteract ac-
quired resistance to EGFR TKI therapy have not yet been
established, and this remains an ongoing challenge for
NSCLC treatment.
In addition, targeted EGFR therapy using erlotinib and
gefitinib preceded a full understanding of their mecha-
nism of action, such that regulatory approval that oc-
curred before EGFR mutational status was identified as
a predictive biomarker for clinical activity [15]. While
the efficacy of these drugs is generally superior to che-
motherapy for individuals whose tumors harbor EGFR
mutations, the incidence of EGFR mutation-positive pa-
tients ranges from approximately 30 % in Asian popula-
tions to only 10–15 % in Western countries [16]. Thus,
the clear majority of NSCLC patients worldwide do not
harbor EGFR mutations, and the value and applicability
of EGFR TKIs within the context of wild-type EGFR
(WT-EGFR) NSCLC are controversial [17–19].
Selective inhibitors of the molecular chaperone heat shock
protein 90 (HSP90) are an actively pursued class of agents
currently under development as novel anticancer therapeutics
[20]. HSP90 plays an essential role in regulating the functional
stability and maturation of numerous key signal transduction
proteins, termed “client” proteins [21]. Notably, a number of
sensitive HSP90 clients have been implicated in the patho-
genesis of NSCLC, including EGFR and anaplastic lympho-
ma kinase (ALK), and intermediates of oncogenic signaling
cascades such as RAF and AKT [22]. Indeed, the chaperone
activity of HSP90 is commonly exploited by cancer cells to
facilitate multiple aspects of the tumorigenic process, includ-
ing aberrant survival, oncogene addiction, and metastatic po-
tential [23, 24]. Because inhibition of HSP90 activity targets
its clients for proteasomal destruction, pharmacological block-
ade of the chaperone provides a mechanism to concomitantly
disrupt multiple oncogenic signaling cascades through a sin-
gular molecular target [25, 26]. Moreover, this unique char-
acteristic also serves as a means to overcome signaling redun-
dancies and drug resistance mechanisms observed in many
cancers [25–27].
Ganetespib is a potent, resorcinol-based small mole-
cule inhibitor of HSP90 that exhibits robust preclinical
activity against a range of cancer models, including
NSCLC [28–31]. Importantly, beyond client-driven tu-
mor types, ganetespib can potentiate the effects of other
molecularly targeted and chemotherapeutic agents while
simultaneously counteracting both intrinsic and acquired
drug resistance in a variety of tumor models (reviewed in
Proia and Bates [29]). Moreover, a maturing clinical
profile has revealed evidence of therapeutic efficacy in
NSCLC, most notably as a single agent in ALK-driven
disease and as part of combination therapy with docetax-
el in advanced adenocarcinoma patients [32, 33]. In light
of these considerations, we sought to determine whether
ganetespib could potentiate EGFR TKI activity within
the context of EGFR mutant NSCLC, using both
erlotinib-sensitive and erlotinib-resistant models. Since
therapeutic response to HSP90 inhibition and EGFR ki-
nase blockade is also of clinical interest for WT-EGFR
lung cancer, we further combined these two modalities in
NSCLC models of this phenotypic background. The data
reported here suggest that ganetespib treatment alongside
EGFR kinase inhibition offers a potentially important
complementary strategy to targeted TKI inhibition alone
for inducing substantial antitumor responses, as well as
overcoming TKI resistance, in both the mutant and WT-
EGFR settings.
Materials and methods
Cell lines, antibodies, and reagents
The NCI-HCC827, NCI-H1975, NCI-H1395, NCI-H1666,
and NCI-H292 cell lines were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA). NCI-
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H322 cells were purchased from Sigma-Aldrich (St. Louis,
MO, USA). All were maintained at 37 °C in 5 % (v/v) CO2
using culture medium recommended by the supplier. The
remaining NSCLC lines listed in Table 1 are part of a collec-
tion assembled by The Center for Molecular Therapeutics
(Massachusetts General Hospital Cancer Center) who per-
formed the drug sensitivity analysis. All primary antibodies
were purchased from Cell Signaling Technology (CST, Bev-
erly, MA, USA) with the exception of p-EGFR (Invitrogen,
Grand Island, NY, USA) and the glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) antibodies (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA). Ganetespib [3-(2,4-dihydroxy-5-
isopropylphenyl)-4-(1-methyl-1H-1,2,4-triazol-5(4H)-one]
was synthesized by Synta Pharmaceuticals Corp. Erlotinib
and afatinib were purchased from LC Laboratories (Woburn,
MA, USA).
Cell viability assays
Cellular viability was assessed using the CellTiter-Glo
Luminescent Cell Viability Assay (Promega, Madison,
WI, USA) according to the manufacturer’s protocol. Lung
cancer cell lines were seeded into 96-well plates based on
optimal growth rates determined empirically for each line.
Twenty-four hours after plating, cells were dosed with
graded concentrations of drug for 72 h. CellTiter-Glo
was added (50 %v/v) to the cells, and the plates incubated
for 10 min prior to luminescent detection in a Victor 2
microplate reader (PerkinElmer, Waltham, MA, USA).
Data were normalized to percent of control, and IC50
values were determined using XLfit software.
Western blotting
Following in vitro assays, tumor cells were disrupted in lysis
buffer (CST) on ice for 10 min. Lysates were clarified by
centrifugation, and equal amounts of proteins resolved by
SDS-PAGE before transfer to nitrocellulose membranes
(Bio-Rad, Hercules, CA, USA). Membranes were blocked
with StartingBlock T20 blocking buffer (Thermo Scientific,
Cambridge,MA, USA) and immunoblotted with the indicated
antibodies. Antibody-antigen complexes were visualized
using an Odyssey system (LI-COR, Lincoln, NE, USA).
NSCLC xenograft tumor models
Female CB-17/severe combined immunodeficient (SCID)
mice (Charles River Laboratories, Wilmington, MA) at 7–
12 weeks of age were maintained in a pathogen-free environ-
ment, and all in vivo procedures were performed in strict
accordance with the NIH Guide for the Care and Use of
Laboratory Animals and approved by the Synta Pharmaceuti-
cals Corp. Institutional Animal Care and Use Committee.
NCI-HCC827, NCI-H1975, NCI-H1666, or NCI-H322 cells
(5×106) were subcutaneously implanted into SCID mice.
Mice bearing established tumors (100–200 mm3) were allo-
cated into treatment groups of eight (n=4 for the NCI-H1666
experiment) exhibiting similar average tumor volumes and
dosed either vehicle, ganetespib (i.v.) formulated in DRD
(10 % DMSO, 18 % Cremophor RH 40, 3.6 % dextrose),
erlotinib (p.o.) formulated in 0.1 % Tween in PBS, or afatinib
(p.o.) formulated in DRD, using the schedules and regimens
indicated. Tumor volumes (V) were calculated by caliper
measurements of the width (W), length (L), and thickness (T)
of each tumor using the formula: V=0.5236(LWT). Tumor
growth inhibition was determined from the change in average
tumor volumes of each treated group relative to the vehicle-
treated, or itself in the case of tumor regression. Statistical
significance was determined using two-way ANOVA follow-
ed by Bonferroni post tests.
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Results
Ganetespib potentiates the activity of TKIs and overcomes
erlotinib resistance in NSCLC tumors driven by activating
EGFR mutations
We and others have previously shown that ganetespib exhibits
robust cytotoxic activity against NSCLC lines harboring a
spectrum of activating EGFR mutations, and moreover,
ganetespib retains potent activity against erlotinib-resistant
NSCLC tumor phenotypes in vitro [28, 34]. To extend these
findings, here we sought to determine whether concurrent
ganetespib exposure could potentiate EGFR TKI activity
in vivo. Initially, SCIDmice bearing NCI-HCC827 xenografts
were dosed with ganetespib and erlotinib, either alone or in
combination, on a weekly dosing schedule (Fig. 1a). NCI-
HCC827 cells express a mutationally activated EGFRDel
E746_A750 receptor and are sensitive to erlotinib treatment. As
expected, weekly administration of erlotinib at 50 mg/kg was
highly efficacious, resulting in 11 % tumor regression. Al-
though an equivalent dose of ganetespib only inhibited tumor
growth by 67 % (i.e., T/C value, 33 %), concurrent adminis-
tration of ganetespib with erlotinib significantly improved the
TKI antitumor response, inducing 67 % tumor regression (p=
0.0003). All treatments were well tolerated, with no signifi-
cant loss of body weights observed over the 5 weeks of dosing
(Fig. 1b).
This capacity to potentiate the activity of erlotinib therefore
prompted an evaluation of combination therapy using the
erlotinib-resistant, EGFRL858R/T790M mutant-expressing
NCI-H1975 NSCLC model. At the molecular level, single-
agent ganetespib treatment resulted in a potent and dose-
dependent destabilization of EGFRL858R/T790M and HER2 in
NCI-H1975 cells (Fig. 2a). This was accompanied by
inactivation of downstream effector pathways including STAT
signaling, the mitogen-activated protein kinase (MAPK) path-
way, and AKT activity, as evidenced by loss of
(phosphorylated) p-STAT3, p-ERK, and p-AKT protein ex-
pression, respectively. These effects were associated with a
concomitant increase in BIM protein levels, a marker of
apoptosis (Fig. 2a). In vivo, erlotinib dosed at its maximally
tolerated dose (MTD) of 200 mg/kg had no antitumor activity,
consistent with the resistant phenotype of these cells (Fig. 2b).
Ganetespib (50 mg/kg) monotherapy was moderately effica-
cious, inhibiting tumor growth by 39 % (T/C value, 61 %).
However, when the two agents were combined, a significant
improvement in efficacy was seen (T/C, 28 %; p<0.0001).
This combinatorial benefit suggested that ganetespib co-
treatment was sufficient to overcome erlotinib resistance in
these tumors.
Next, we evaluated combinations of ganetespib with
afatinib [35], which has reported antiproliferative activity in
preclinical models expressing T790M [36] and was recently
approved as a first-line oral treatment for NSCLC with EGFR
exon 19 deletions or exon 21 (L858R) substitution mutations.
In vitro, treatment of NCI-H1975 cells with 100 nM
ganetespib resulted in robust degradation of EGFR protein
expression and concomitant reductions in p-EGFR activity, as
well as loss of activated (phosphorylated) forms of MEK and
ERK. Consistent with its TKImode of action, afatinib reduced
EGFR activity (as evidenced by reduced p-EGFR expression)
without affecting total receptor levels (Fig. 2c). Combination
treatment using a constant dose of ganetespib (100 nM) with
increasing concentrations of afatinib indicated that ganetespib
exposure could potentiate the activity of the TKI, sufficient to
cause complete abrogation of EGFR activity and downstream
effector signaling (Fig. 2c). Interestingly, combination treat-
ment appeared to partially stabilize total EGFR protein levels
Fig. 1 Ganetespib confers superior antitumor efficacy in combination
with erlotinib in NCI-HCC827 NSCLC xenografts. aMice bearing NCI-
HCC827 tumors (n=8 mice/group) were i.v. administered ganetespib or
p.o. dosed with erlotinib (each at 50 mg/kg) on a weekly dosing regimen,
either alone or in combination. Data are expressed as mean and SEM for
each time point. Numerical T/C values are indicated to the right of each
growth curve. Combinatorial ganetespib plus erlotinib therapy was sig-
nificantly more efficacious than either agent alone (combination vs.
erlotinib, *p=0.0003). b Body weights were measured five times per
week for the first 2 weeks of dosing and twice per week thereafter. Mean
values are plotted against vehicle controls
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in an afatinib-based, dose-dependentmanner. Despite this, this
pool of receptors lacked activity, as p-EGFR levels continued
to decline in the presence of ganetespib. To determine whether
these responses translated into improved efficacy in vivo, we
subsequently evaluated single agent and combination regi-
mens in NCI-H1975 xenografts. As single agents, weekly
administration of ganetespib (50 mg/kg) and afatinib
(5 mg/kg) dosed five times/week each induced a similar
degree of tumor growth inhibition in NCI-H1975 xenografts
(T/C values, 59 % and 66 %, respectively) (Fig. 2d). Combi-
nation treatment resulted in a significant (p<0.0001) enhance-
ment of antitumor activity, inhibiting tumor growth by 81 %
(Fig. 2d). Moreover, ganetespib co-treatment significantly
potentiated afatinib activity even at a more efficacious
dose of the TKI (Fig. 2e). Afatinib dosed at 20 mg/kg
resulted in effective stabilization of NCI-H1975 xeno-
graft tumor growth (T/C, 6 %), with dual therapy causing
78 % tumor regression (p<0.0001). All treatments were
well tolerated, with no significant toxicity or loss of
body weights observed over the course of the dosing
regimen (Supplementary Fig. S1). Taken together, these
data indicated that ganetespib possesses potent sensitiz-
ing properties when combined with standard of care TKI
drugs in EGFR mutant-driven NSCLC.
Fig. 2 Combinations of ganetespib with EGFRTKIs overcome erlotinib
resistance and confer superior antitumor efficacy in NCI-H1975 NSCLC
xenografts. a NCI-H1975 cells were incubated with the indicated con-
centrations of ganetespib for 24 h. Cell lysates were analyzed byWestern
blotting. bMice bearing NCI-H1975 tumors (n=8 mice/group) were i.v.
administered ganetespib (50 mg/kg) or p.o. dosed with erlotinib
(200 mg/kg) on a weekly dosing regimen, either alone or in combination.
Data are expressed as mean and SEM for each time point. Numerical T/C
values are indicated to the right of each growth curve. Erlotinib mono-
therapy had no activity in this resistant xenograft model; however, the
combination of ganetespib and erlotinib was significantly more effica-
cious than ganetespib treatment alone (*p<0.0001). c NCI-H1975 cells
were incubated with the indicated concentrations of ganetespib or
afatinib, both alone and in combination, for 24 h. Cell lysates were
analyzed by Western blotting. d Mice bearing NCI-H1975 tumors (n=8
mice/group) were i.v. dosed with ganetespib (50 mg/kg) once weekly and
afatinib (5 mg/kg) administered p.o. five times/week, either alone or in
combination. Combinatorial ganetespib plus afatinib therapy was signif-
icantly more efficacious than either agent alone (*p<0.001). e Mice
bearing NCI-H1975 tumors (n=8 mice/group) were i.v. dosed with
ganetespib (50 mg/kg) once weekly and afatinib (20 mg/kg) administered
p.o. five times/week, either alone or in combination. The combination of
ganetespib and erlotinib was significantly more efficacious than single-
agent therapy, resulting in tumor regressions (*p<0.0001)
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Characterizing ganetespib activity in WT-EGFR NSCLC
models
To investigate ganetespib activity within the context of the
WT-EGFR phenotype, the cytotoxic activity of the compound
was first evaluated using a panel of 31 WT-EGFR-expressing
NSCLC lines, where it reduced cell viability with low
nanomolar potency (Table 1). Our analysis included the
NCI-H1838 cell line which exhibits genomic amplification
of EGFR, resulting in overexpression of the wild-type recep-
tor [37]. Ganetespib had a cytotoxicity IC50 value in these
cells of 21 nM, virtually identical to the overall median value
for all the lines examined (22 nM). Expression changes in
HSP90 client proteins and signaling pathways associated with
NSCLC progression were then investigated using the
ganetespib-sensitive, WT-EGFR cell line NCI-H1666. As
expected, targeted degradation of both EGFR and HER2
receptor expression was induced in a dose-dependent manner,
with maximal effects achieved at drug concentrations of
100 nM or greater (Fig. 3a). Of note, NCI-H1666 cells harbor
a mutant BRAFG466V kinase. Mutant BRAF proteins are
particularly reliant on HSP90 activity for stability, and accord-
ingly, destabilization of BRAFG466V protein levels also oc-
curred following ganetespib treatment. However, in contrast
Fig. 3 Ganetespib inhibits
oncogenic signaling and
suppresses tumor growth in WT-
EGFR NSCLC models. a NCI-
H1666 cells were incubated with
the indicated concentrations of
ganetespib for 24 h. Cell lysates
were analyzed by Western
blotting. b NCI-H1666 cells were
treated with 100 nM ganetespib
for the indicated time periods.
Cell lysates were analyzed by




(150 mg/kg) on a weekly dosing
regimen for 3 weeks. Data are
expressed as mean and SEM for
each time point. Numerical T/C
values are indicated to the right of
each growth curve
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to most other BRAF mutations (e.g., BRAFV600E) which are
activating and confer transforming capacity, BRAFG466V is
kinase impaired [38] and thus not likely to be a primary driver
of oncogenesis in this cell line. The coordinate impacts on
these upstream signaling mediators arising from ganetespib
treatment produced convergent effects onMAPK and survival
pathway signaling (Fig. 3a). This was demonstrated by the
complete loss of active (phosphorylated) MEK and AKT
expression, as well as significantly reduced ERK activity, seen
at comparable drug concentrations. These molecular changes
correlated with a robust increase in cleaved poly(ADP-ribose)
polymerase (PARP) expression, another marker of apoptosis
(Fig. 3a).
When the kinetics of client pathway modulation in re-
sponse to HSP90 inhibition were examined (Fig. 3b), it was
found that 100-nM ganetespib treatment promoted the desta-
bilization of WT-EGFR which was most evident at the 16-h
time point. By comparison, a more rapid loss of HER2
protein expression was achieved, occurring by 6 h. These
data are in agreement with the differential sensitivity of the
two receptors to pharmacological HSP90 blockade. Inter-
estingly, we observed a transient rebound in p-AKT ex-
pression between 2 and 6 h following ganetespib exposure;
however, this cellular response was effectively suppressed
in the continued presence of the HSP90 inhibitor. Overall,
the kinetics for maximal reductions in MEK, ERK, and
AKT activities matched those observed for the elevation of
cleaved PARP levels (Fig. 3b).
To determine whether these effects on viability and cell
signaling translated to antitumor activity in vivo, we evaluated
the single-agent efficacy of ganetespib treatment on the
growth of NCI-H1666 xenografts. As shown in Fig. 3c, mice
bearing NCI-H1666 tumors that were treated on a weekly
dosing schedule of ganetespib at its MTD of 150 mg/kg [28]
exhibited a significant decrease in tumor growth, resulting in
12 % tumor regression. Thus, the potent and durable loss of
client protein expression and perturbation of oncogenic sig-
naling induced by ganetespib exposure effectively suppressed
tumor growth in this WT-EGFR NSCLC model.
Combination ganetespib plus erlotinib treatment induces
tumor regressions in WT-EGFR NSCLC
Combinatorial erlotinib plus ganetespib treatment was subse-
quently evaluated in an additional NSCLC model of WT-
EGFR background. To minimize any confounding oncogenic
driver effects, the NCI-H322 cell line was chosen for these
experiments as it is wild-type for EGFR, BRAF, as well as
KRAS. Consistent with its mode of action, erlotinib alone had
no effect on total EGFR protein levels but did reduce EGFR
phosphorylative status in NCI-H322 cells (Fig. 4a). At the
highest dose levels examined, a reduction in ERK activity
(i.e., p-ERK expression) and modest impact on AKTsignaling
were observed. A high dose of ganetespib (500 nM) was
sufficient to effectively degrade EGFR protein levels (induc-
ing a concomitant loss of p-EGFR activity), abrogate AKT
signaling, and reduce, although not completely inhibit,
p-ERK expression in NCI-H322 cells. In the presence of
ganetespib, and similar to what was observed for the
ganetespib/afatinib combination in Fig. 2c, concurrent treat-
ment with increasing concentrations of erlotinib partially sta-
bilized EGFR protein levels in a dose-dependent manner.
Despite this, no reactivation of EGFR kinase activity, as
evidenced by p-EGFR expression, occurred with concomitant
ganetespib exposure. In addition, ERK signaling activity was
further suppressed in an erlotinib-dependent manner in
combination-treated NCI-H322 cells (Fig. 4a). Similar
Fig. 4 Ganetespib potentiates the activity of erlotinib to induce tumor
regression in WT-EGFR NSCLC. a NCI-H322 cells were incubated with
the graded concentrations of erlotinib for 24 h, with or without 500 nM
ganetespib. Cell lysates were analyzed by Western blotting. b Mice
bearing NCI-H322 tumors (n=8 mice/group) were i.v. dosed with
ganetespib (50 mg/kg) once weekly and erlotinib (25 mg/kg)
administered p.o. five times/week, either alone or in combination. Nu-
merical T/C values are indicated to the right of each growth curve, and the
errors bars are the SEM. The combination of ganetespib and erlotinib
was significantly more efficacious than either agent alone, resulting in
tumor regressions (combination vs. erlotinib, *p<0.0001)
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molecular effects and pathway modulation were observed in
another WT-EGFR cell line, NCI-H292 (Supplementary
Fig. S2).
Finally, we performed an extended in vivo analysis of
combination ganetespib plus erlotinib treatment using NCI-
H322 xenografts. Mice bearing NCI-H322 tumors were treat-
ed with a one third MTD (50 mg/kg) weekly dose of
ganetespib or erlotinib (25 mg/kg) five times/week, either
alone or in combination, over a 2-month treatment period
(Fig. 4b). Ganetespib monotherapy resulted in 38 % tumor
growth inhibition, while erlotinib suppressed tumor growth by
65%.When administered concurrently, a significant improve-
ment in antitumor efficacy was achieved, resulting in 34 %
tumor regression. These data clearly demonstrate that the
therapeutic sensitizing properties of ganetespib for direct
EGFR kinase inhibition were conserved within the WT-
EGFR NSCLC setting.
Discussion
EGFR is a validated therapeutic target in NSCLC, with three
small molecule TKIs (erlotinib, gefitinib, and afatinib) cur-
rently approved for the treatment of advanced disease [22]. All
of these agents show preferential clinical efficacy in NSCLC
patients whose tumors harbor activating EGFR mutations.
Mutant EGFR oncoproteins are particularly reliant on the
chaperone activity of HSP90 for their conformational stability
and function [39, 40]. Thus, pharmacological blockade of
HSP90, leading to the degradation and loss of mutant EGFR
protein, is considered a rational and alternative strategy to TKI
inhibition for treating tumors driven by such genetic modifi-
cations. Moreover, it has recently been demonstrated that the
mature, wild-type receptor is also a bona fide HSP90 client in
cancers that overexpress WT-EGFR [41], suggesting potential
utility for targeted HSP90 inhibitors beyond the mutant recep-
tor phenotype. Despite this, the clinical experience with
ganetespib (and other selective HSP90 inhibitors) has re-
vealed only modest single-agent activity in molecularly de-
fined subsets of both wild-type and mutant EGFR NSCLC
patients [32, 42]. It has been proposed that the full therapeutic
benefit of small molecule inhibitors of HSP90 is likely to be
realized when they are used as part of combinatorial ap-
proaches, alongside standard-of-care or other molecularly
targeted agents [20]. In this regard, ganetespib has shown
potent chemosensitizing activity when administered in con-
junction with taxanes in NSCLC, in both the preclinical and
clinical settings [30, 33]. These considerations thus prompted
the comprehensive evaluation of combining the modalities of
HSP90 blockade with selective EGFR tyrosine kinase inhibi-
tion presented here.
Initially, we performed analyses using xenograft tumors
derived from the mutant EGFRDel E746_A750-driven NCI-
HCC827 NSCLC cell line, wherein the presence of this par-
ticular mutation confers sensitivity to erlotinib exposure. In-
deed, erlotinib treatment was highly efficacious in vivo,
resulting in measurable tumor regressions and disease stabili-
zation. Since mutated EGFR is an established HSP90 client
and NCI-HCC827 cells are sensitive to ganetespib exposure
[28], we selected a low (one thirdMTD) dose of ganetespib for
these experiments in order to readily permit evaluation of
potential combinatorial improvements in efficacy between the
two drugs. As a single agent, ganetespib displayed only modest
antitumor activity at this dose level. However, when combined
with erlotinib, ganetespib greatly improved the therapeutic
response, significantly enhancing the overall degree of regres-
sion in this model. The molecular basis underlying the superior
efficacy remains to be fully elucidated. However, it is reason-
able to suggest that coordinate impacts on both the signaling
activity and functional stability of EGFRDel E746_A750 (afforded
by selective kinase and HSP90 inhibition, respectively) pro-
moted a more robust and durable loss of EGFR oncogenic
driver activity that resulted in greater tumor shrinkage. Further,
the pleiotropic effects of HSP90 inhibition would also be
expected to impact convergent and/or parallel signaling path-
ways to EGFR; this broader spectrum of biologic activity
might also contribute to the improved therapeutic indices.
While initially effective in appropriately selected NSCLC
populations, durable responses to erlotinib are rare, and most
patients invariably progress to drug-resistant disease, typically
within around 12 months [43]. The predominant mechanism
of acquired resistance, accounting for approximately half of
all cases, is the acquisition of a secondary mutation (T790M)
at the gatekeeper residue of EGFR [43]. Indeed, the higher
prevalence of this mutation in patients previously treated with
an EGFR TKI indicates that TKI therapy itself provides a
strong selection pressure for this molecular alteration and
consequent development of resistance [44]. We have previ-
ously reported that erlotinib-resistant, EGFRL858R/T790M
mutant-expressing NCI-H1975 cells display sensitivity to
ganetespib [28] and, as we show here, this results from potent
destabilization and loss of EGFRL858R/T790M receptor expres-
sion, with concomitant effects on downstream effector path-
ways including STAT, ERK, and AKT signaling. This is
consistent with the premise that tumors that have become
erlotinib-resistant via secondary T790M mutation are still
dependent on aberrant EGFR activity for their continued
growth and survival. As expected, NCI-H1975 xenograft
tumors were insensitive to erlotinib treatment, and a one third
MTD dose of ganetespib resulted in a modest degree of tumor
growth inhibition when administered as monotherapy. How-
ever, concurrent treatment with both drugs resulted in a sig-
nificantly improved antitumor response, indicating that dual
ganetespib+erlotinib therapy may provide a means to
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overcome erlotinib resistance in this clinically relevant
NSCLC model. This result is in agreement with a preclinical
study showing similar combinatorial benefit when erlotinib
was combined with an investigational HSP90 inhibitor com-
pound CH5164840 [45]. Encouraging signs of clinical activ-
ity with the HSP90 inhibitor AUY922, dosed in combination
with erlotinib, in patients with acquired resistance to EGFR
inhibitors was recently reported from a phase II study
(NCT01259089) [46]. Five of 22 patients demonstrated a
partial response; three of which had the T790M mutation.
Together, the data suggest that HSP90 inhibition alongside
EGFR kinase blockade may represent an effective drug com-
bination for overcoming TKI resistance in EGFR-mutant
NSCLC.
One approach to counteract T790M-mediated resistance
mechanisms has been the development of irreversible TKIs,
such as the dual EGFR/HER inhibitor afatinib. Unlike erloti-
nib and gefitinib, which are reversible ATP-competitive
agents, afatinib covalently binds to EGFR to irreversibly
block receptor tyrosine kinase activity [35]. Accordingly,
afatinib has shown robust activity in preclinical models
against tumor lines harboring the T790M mutation, including
NCI-H1975 [36]. Interestingly, our study also uncovered a
significant enhancement of afatinib antitumor efficacy in re-
sponse to ganetespib co-treatment in these xenograft tumors.
At suboptimal dose levels that each induced a similar degree
of tumor growth inhibition as single agents, combination
treatment of ganetespib with afatinib resulted in a significant
enhancement of tumor suppression. Remarkably, even at a
more efficacious afatinib dose that effectively inhibited tumor
growth, the addition of ganetespib to the regimen promoted
near-complete tumor regressions. While the precise mecha-
nism(s) by which ganetespib potentiates the activity of EFGR
TKIs of both the reversible and irreversible classes is currently
under investigation, further evaluation of this combinatorial
treatment strategy is warranted. In this regard, an early-stage
clinical trial combining ganetespib with afatinib in NSCLC
patients with EGFR-activating mutations and acquired erloti-
nib resistance is planned.
A significant finding of the present study was that the
improved therapeutic efficacy afforded by combination
ganetespib plus erlotinib treatment was also observed within
the WT-EGFR NSCLC setting. These data also provided
some insights to the molecular mechanisms underlying the
interaction between kinase and HSP90 inhibition. While erlo-
tinib treatment resulted in a degree of receptor stabilization, no
reactivation of EGFR kinase activity was observed in the
presence of ganetespib. In addition, ERK signaling appeared
to represent a point of convergence between the two agents,
given that ERK activity was completely suppressed in cells
following dual drug treatment. In contrast to its established
role as first-line therapy for NSCLC patients with EGFR-
mutated tumors, the use of erlotinib as a second- or third-
line salvage treatment for WT-EGFR patients that have
progressed on prior chemotherapy remains contentious [18].
For example, the recent TAILOR phase III trial comparing
erlotinib with docetaxel in advanced NSCLC patients with
WT-EGFR tumors for whom first-line platinum therapy had
failed demonstrated a clear superiority for the standard che-
motherapy arm [47]. However, the initial clinical evaluation of
erlotinib was performed in unselected NSCLC populations,
and retrospective analyses of those randomized trials has
revealed that, while overall response rates were higher in
patients with EGFR mutations, survival benefit from single-
agent erlotinib treatment was maintained in a proportion of the
wild-type population [15, 48]. The underlyingmolecular basis
for the modest, yet clinically meaningful, improvements in
survival outcomes forWT-EGFR individuals is still unknown,
and biomarkers predicting for TKI response in WT-EGFR
patients are lacking [17]. Moreover, there is considerable
interest in identifying strategies to both exploit and improve
the efficacy of selective TKIs such as erlotinib in wild-type
disease. To date, efforts to combine EGFRTKIs with standard
chemotherapies have not been associated with survival bene-
fits in clinical trials [5]. The data presented here suggest that
the multimodal effects afforded by HSP90 inhibition may
represent a novel approach for optimizing response to EGFR
TKIs for the large majority of NSCLC cases and thus warrant
further clinical investigation.
Overall, the capacity of ganetespib to potentiate the in vivo
activity of selective EGFR TKIs (including erlotinib and
afatinib) provides a compelling rationale for combining these
agents as part of novel treatment strategies for NSCLC. More-
over, the therapeutic benefit conferred by dual HSP90/EGFR-
TKI blockade was conserved within both the mutant and WT-
EGFR disease settings—thus providing new opportunities to
target EGFR and overcome mechanisms of resistance across a
spectrum of NSCLC patients.
Acknowledgments The authors would like to thank Kevin Foley for
his contribution to the experimental design during the genesis of these
studies.
Conflict of interest Dr. Smith has nothing to disclose. Dr. Acquaviva
has nothing to disclose. Dr. Sequeira has nothing to disclose. Dr. Jimenez
has nothing to disclose. Dr. Zhang has nothing to disclose. Dr. Sang has
nothing to disclose. Dr. Bates has nothing to disclose. Dr. Proia has
nothing to disclose.
Ethical standards The manuscript does not contain clinical studies or
patient data.
Open AccessThis article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any non-
commercial use, distribution, and reproduction in any medium, provided
the original author(s) and the source are credited.
Targ Oncol (2015) 10:235–245 243
References
1. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns
of cancer incidence and mortality rates and trends. Cancer Epidemiol
Biomarkers Prev 19:1893–1907
2. Siegel R, NaishadhamD, Jemal A (2013) Cancer statistics, 2013. CA
Cancer J Clin 63:11–30
3. Ramalingam S, Belani C (2008) Systemic chemotherapy for ad-
vanced non-small cell lung cancer: recent advances and future direc-
tions. Oncologist 13(Suppl 1):5–13
4. Grossi F, Kubota K, Cappuzzo F, deMarinis F, Gridelli C et al (2010)
Future scenarios for the treatment of advanced non-small cell lung
cancer: focus on taxane-containing regimens. Oncologist 15:1102–
1112
5. Ramalingam SS, Owonikoko TK, Khuri FR (2011) Lung cancer:
new biological insights and recent therapeutic advances. CACancer J
Clin 61:91–112
6. Gaughan EM, Costa DB (2011) Genotype-driven therapies for non-
small cell lung cancer: focus on EGFR, KRAS and ALK gene
abnormalities. Ther Adv Med Oncol 3:113–125
7. Herbst RS, Lynch TJ, Sandler AB (2009) Beyond doublet chemo-
therapy for advanced non-small-cell lung cancer: combination of
targeted agents with first-line chemotherapy. Clin Lung Cancer 10:
20–27
8. Stella GM, Luisetti M, Inghilleri S, Cemmi F, Scabini R et al (2012)
Targeting EGFR in non-small-cell lung cancer: lessons, experiences,
strategies. Respir Med 106:173–183
9. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR (2004) Clin Cancer
Res 10:4227s–4232s
10. Ono M, Kuwano M (2006) Molecular mechanisms of epidermal
growth factor receptor (EGFR) activation and response to gefi-
tinib and other EGFR-targeting drugs. Clin Cancer Res 12:7242–
7251
11. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal
growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:
169–181
12. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O et al
(2005) EGFR mutation and resistance of non-small-cell lung cancer
to gefitinib. N Engl J Med 352:786–792
13. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R et al (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib
is associated with a second mutation in the EGFR kinase domain.
PLoS Med 2:e73
14. Carrera S, Buque A, Azkona E, Aresti U, Calvo B et al (2014)
Epidermal growth factor receptor tyrosine-kinase inhibitor treatment
resistance in non-small cell lung cancer: biological basis and thera-
peutic strategies. Clin Transl Oncol 16:339–350
15. Jazieh AR, Al Sudairy R, Abu-Shraie N, Al Suwairi W, Ferwana M
et al (2013) Erlotinib in wild type epidermal growth factor receptor
non-small cell lung cancer: a systematic review. Ann Thorac Med 8:
204–208
16. Gazdar AF (2009) Activating and resistance mutations of EGFR in
non-small-cell lung cancer: role in clinical response to EGFR tyrosine
kinase inhibitors. Oncogene 28(Suppl 1):S24–31
17. Laurie SA, Goss GD (2013) Role of epidermal growth factor receptor
inhibitors in epidermal growth factor receptor wild-type non-small-
cell lung cancer. J Clin Oncol 31:1061–1069
18. Gelsomino F, Agustoni F, Niger M, Valota M, Haspinger ER (2013)
Epidermal growth factor receptor tyrosine kinase inhibitor treatment
in patients with EGFR wild-type non-small-cell lung cancer: the
never-ending story. J Clin Oncol 31:3291–3293
19. Jassem J, Dziadziuszko R (2013) EGFR inhibitors for wild-type
EGFR NSCLC: to use or not to use? Lancet Oncol 14:916–917
20. Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibi-
tors: are we there yet? Clin Cancer Res 18:64–76
21. TaipaleM, JaroszDF, Lindquist S (2010) HSP90 at the hub of protein
homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol
11:515–528
22. Reungwetwattana T, Dy GK (2013) Targeted therapies in develop-
ment for non-small cell lung cancer. J Carcinog 12:22
23. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of
cancer. Nat Rev Cancer 5:761–772
24. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the
dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537–549
25. Xu W, Neckers L (2007) Targeting the molecular chaperone heat
shock protein 90 provides a multifaceted effect on diverse cell sig-
naling pathways of cancer cells. Clin Cancer Res 13:1625–1629
26. Banerji U (2009) Heat shock protein 90 as a drug target: some like it
hot. Clin Cancer Res 15:9–14
27. Neckers L (2007) Heat shock protein 90: the cancer chaperone. J
Biosci 32:517–530
28. Ying W, Du Z, Sun L, Foley KP, Proia DA et al (2012) Ganetespib, a
unique triazolone-containing Hsp90 inhibitor, exhibits potent antitu-
mor activity and a superior safety profile for cancer therapy. Mol
Cancer Ther 11:475–484
29. Proia DA, Bates RC (2014) Ganetespib and HSP90: translating
preclinical hypotheses into clinical promise. Cancer Res 74:1294–
1300
30. Proia DA, Sang J, He S, Smith DL, Sequeira M et al (2012)
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes
in non-small cell lung cancer models. Investig New Drug 30:2201–
2209
31. Acquaviva J, Smith DL, Sang J, Friedland JC, He S et al (2012)
Targeting KRAS-mutant non-small cell lung cancer with the Hsp90
inhibitor ganetespib. Mol Cancer Ther 11:2633–2643
32. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic Vet al
(2013) A multicenter phase II study of ganetespib monotherapy in
patients with genotypically defined advanced non-small cell lung
cancer. Clin Cancer Res 19:3068–3077
33. Ramalingam S, Goss GD, Andric ZG, Bondarenko I, Zaric B, et al
(2013) A randomized study of ganetespib, a heat shock protein 90
inhibitor, in combination with docetaxel versus docetaxel alone for
second-line therapy of lung adenocarcinoma (GALAXY-1). J Clin
Oncol 31:abstr CRA8007
34. Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ et al (2012)
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has
potent antitumor activity in in vitro and in vivo models of non-small
cell lung cancer. Clin Cancer Res 18:4973–4985
35. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M et al (2012)
Target binding properties and cellular activity of afatinib (BIBW
2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther
343:342–350
36. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M et al (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in
preclinical lung cancer models. Oncogene 27:4702–4711
37. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W et al (2005)
Epithelial versus mesenchymal phenotype determines in vitro sensi-
tivity and predicts clinical activity of erlotinib in lung cancer patients.
Clin Cancer Res 11:8686–8698
38. Sen B, Peng S, Tang X, Erickson HS, Galindo H et al (2012) Kinase-
impaired BRAF mutations in lung cancer confer sensitivity to
dasatinib. Sci Transl Med 4:136ra170
39. Shimamura T, Lowell AM, Engelman JA, Shapiro GI (2005)
Epidermal growth factor receptors harboring kinase domain muta-
tions associate with the heat shock protein 90 chaperone and are
destabilized following exposure to geldanamycins. Cancer Res 65:
6401–6408
40. Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E et al
(2008) Hsp90 inhibition suppresses mutant EGFR-T790M sig-
naling and overcomes kinase inhibitor resistance. Cancer Res
68:5827–5838
244 Targ Oncol (2015) 10:235–245
41. Ahsan A, Ramanand SG, Whitehead C, Hiniker SM,
Rehemtulla A et al (2012) Wild-type EGFR is stabilized by
direct interaction with HSP90 in cancer cells and tumors. Neoplasia
14:670–677
42. Sequist LV, Gettinger S, Senzer NN, Martins RG, Janne PA et al
(2010) Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in
patients with molecularly defined non-small-cell lung cancer. J Clin
Oncol 28:4953–4960
43. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S,
Turke AB et al (2011) Genotypic and histological evolution of
lung cancers acquiring resistance to EGFR inhibitors. Sci
Transl Med 3:75ra26
44. Su KY, Chen HY, Li KC, Kuo ML, Yang JC et al (2012)
Pretreatment epidermal growth factor receptor (EGFR) T790M
mutation predicts shorter EGFR tyrosine kinase inhibitor re-
sponse duration in patients with non-small-cell lung cancer. J
Clin Oncol 30:433–440
45. Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K et al (2013)
Enhanced antitumor activity of erlotinib in combination with the
Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
Cancer Sci 104:1346–1352
46. Johnson ML, Hart EM, Rademaker A, Weitner BB, Urman A, et al
(2013) A phase II study of HSP90 inhibitor AUY922 and erlotinib
(E) for patients (pts) with EGFR-mutant lung cancer and acquired
resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs). J
Clin Oncol 31:abstr 8036
47. Garassino MC, Martelli O, Broggini M, Farina G, Veronese S et al
(2013) Erlotinib versus docetaxel as second-line treatment of patients
with advanced non-small-cell lung cancer and wild-type EGFR tu-
mours (TAILOR): a randomised controlled trial. Lancet Oncol 14:
981–988
48. Piperdi B, Perez-Soler R (2012) Role of erlotinib in the treatment of
non-small cell lung cancer: clinical outcomes in wild-type epidermal
growth factor receptor patients. Drugs 72(Suppl 1):11–19
Targ Oncol (2015) 10:235–245 245
